Back

dr. F.Y.F.L. (Filip) de Vos

Assistant Professor - medical

Show full profile

Research Output (70)

Reducing uncertainty:motivations and consequences of seeking a second opinion in oncology

Lehmann Vicky, Smets Ellen M A, de Jong Maxime, de Vos Filip Y F, Kenter Gemma G, Stouthard Jacqueline M, Hillen Marij A 1 dec 2020, In: Acta Oncologica. 59 , p. 1512-1519 8 p.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Gutierrez Martin, Moreno Victor, Heinhuis Kimberley M, Olszanski Anthony J, Spreafico Anna, Ong Michael, Chu Quincy S, Carvajal Richard D, Trigo José, Ochoa de Olza Maria, Provencio Mariano, De Vos Filip, de Braud Filippo, Leong Stephen, Lathers Deanne, Wang Rui, Ravindran Palani, Feng Yan, Aanur Praveen, Melero Ignacio 4 nov 2020, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 27 , p. 460-472 13 p.

Herziene richtlijn ‘Hersenmetastasen’

Hilkens Nina A, Enting Roelien H, Hendriks Lizza E L, Lagerwaard Frank J, de Vos Filip Y F L, Gijtenbeek J M M 8 okt 2020, In: Nederlands Tijdschrift voor Geneeskunde. 164 , p. D5233

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel Robin M J M, van Brummelen Emilie M J, Eskens Ferry A L M, Huijberts Sanne C F A, de Vos Filip Y F L, Lolkema Martijn P J K, Devriese Lot A, Opdam Frans L, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin D R, Beijnen Jos H, Bernards René, Schellens Jan H M 9 mrt 2020, In: British Journal of Cancer. 122 , p. 1166-1174 9 p.

Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Priesterbach-Ackley L P, Boldt H B, Petersen J K, Bervoets N, Scheie D, Ulhøi B P, Gardberg M, Brännström T, Torp S H, Aronica E, Küsters B, den Dunnen W F A, de Vos F Y F L, Wesseling P, de Leng W W J, Kristensen B W 18 feb 2020, In: Neuropathology and Applied Neurobiology. 46 , p. 478-492 15 p.

Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy

Sharma Padmanee, Sohn Joohyuk, Shin Sang Joon, Oh Do Youn, Keam Bhumsuk, Lee Hyo Jin, Gizzi Marco, Kalinka Ewa, de Vos Filip Y.F.L., Ruscica Dario, Ferro Salvatore, Xiao Feng, Baverel Paul, Chen Cecil Chi Keung, Asubonteng Kobby, Morsli Nassim, Dirix Luc 1 jan 2020, In: Clinical Cancer Research. 26 , p. 61-70 10 p.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent Martin, Azaro Analia, De Vos Filip, Sepulveda Juan, Yung W. K.Alfred, Wen Patrick Y., Lassman Andrew B., Joerger Markus, Tabatabai Ghazaleh, Rodon Jordi, Tiedt Ralph, Zhao Sylvia, Kirsilae Tiina, Cheng Yi, Vicente Sergio, Balbin O. Alejandro, Zhang Hefei, Wick Wolfgang 1 jan 2020, In: Journal of Neuro-Oncology. 146 , p. 79-89 11 p.

Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies

Noorlag Lotte, De Vos Filip Y., Kok Annemieke, Broekman Marike L. D., Seute Tatjana, Robe Pierre A., Snijders Tom J. okt 2019, In: Clinical Nutrition. 38 , p. 1986-1994 9 p.

Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation

Van Seggelen Wouter O., De Vos Filip Y., Röckmann Heike, Van Dijk Marijke R., Verhoeff Joost J.C. 1 sep 2019, In: Case Reports in Oncology. 12 , p. 896-900 5 p.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck W. Larry, Gounder Mrinal M., Frank Richard, Eskens Ferry, Blay Jean Yves, Cassier Philippe A., Soria Jean Charles, Chawla Sant, de Weger Vincent, Wagner Andrew J., Siegel David, De Vos Filip, Rasmussen Erik, Henary Haby A. 29 jul 2019, In: Investigational New Drugs. 38 , p. 831-843 13 p.